Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 1,610 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, December 17th, Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $196.03, for a total value of $123,302.87.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $1.19 during trading on Friday, reaching $207.16. 1,571,166 shares of the company traded hands, compared to its average volume of 1,659,007. The firm has a market capitalization of $59.02 billion, a PE ratio of 35.53, a PEG ratio of 2.29 and a beta of 0.23. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $195.30 and its two-hundred day moving average is $189.07.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the previous year, the firm earned $3.81 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a dividend of $1.05 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.0%. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Institutional Trading of Becton, Dickinson and Company

A number of large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after buying an additional 4,305,947 shares during the last quarter. Norges Bank bought a new stake in shares of Becton, Dickinson and Company in the second quarter valued at $653,377,000. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after buying an additional 3,268,478 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Becton, Dickinson and Company by 24.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after acquiring an additional 1,670,590 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of several research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 17th. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Finally, Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.